Ovarian cancer remains the leading cause of death among women with gynecologic malignancies in the United States. Most women with epithelial ovarian cancer present with advanced disease. Despite good response rates to initial surgery and chemotherapy, the majority of patients experience relapse and ultimately die of their disease. A better understanding of the molecular differences underlying the histologic subtypes of epithelial ovarian cancer has led to recent advances in targeted therapeutic strategies. Here we review the most promising targeted therapeutics currently being used for the treatment of recurrent ovarian cancer.